Colesevelam Hydrochloride (Cholestagel)

Open Access

13 September 1999

journal article
clinical trial
Published by American Medical Association (AMA) in Archives of internal medicine (1960)

Vol. 159 (16) , 1893-1900
https://doi.org/10.1001/archinte.159.16.1893

Abstract

ELEVATED SERUM concentrations of cholesterol, particularly low-density lipoprotein (LDL) cholesterol, constitute a risk factor for the development of coronary heart disease (CHD).¹^-3 A direct correlation exists between hypercholesterolemia and cardiovascular disease mortality and morbidity.⁴^,5 Clinical trials have demonstrated that aggressive reduction of lipid levels reduces this risk in patients with and without CHD.¹^,6^,7 In fact, each 1% reduction of LDL cholesterol lowers the risk of CHD by 2%.¹^,8 Diet and lifestyle interventions are generally the first steps taken toward reducing lipid levels but often have small and inconsistent effects. Therefore, pharmacological measures are necessary for those patients who continue to have elevated lipid levels following diet and lifestyle changes.⁹

This publication has 1 reference indexed in Scilit:

How effective is drug therapy in heterozygous familial hypercholesterolemia?
The American Journal of Cardiology, 1993